# Open-Label Safety Extension Study of Avonex

> **NCT00915460** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 408 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1a (Avonex)

## Key facts

- **NCT ID:** NCT00915460
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** 2003-06
- **Final completion:** 2003-07
- **Target enrollment:** 408 (ACTUAL)
- **Last updated:** 2009-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00915460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00915460, "Open-Label Safety Extension Study of Avonex". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00915460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*